A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma |
| |
| Institution: | 1. Susan F. Smith Center for Women''s Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston;2. Division of Hematology and Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia;3. Division of Hematology and Medical Oncology, University of California San Francisco Helen Diller Comprehensive Cancer Center, San Francisco;4. Division of Hematology/Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis;5. Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston;6. Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston;7. Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston;8. Pfizer, Inc., New York, USA |
| |
| Abstract: | BackgroundThe CDK4/6 inhibitor palbociclib prolongs progression-free survival in hormone receptor-positive/HER2-negative (HR+/HER2?) metastatic breast cancer when combined with endocrine therapy. This phase II trial was designed to determine the feasibility of adjuvant palbociclib and endocrine therapy for early breast cancer.Patients and methodsEligible patients with HR+/HER2? stage II–III breast cancer received 2 years of palbociclib at 125 mg daily, 3 weeks on/1 week off, with endocrine therapy. The primary end point was discontinuation from palbociclib due to toxicity, non-adherence, or events related to tolerability. A discontinuation rate of 48% or higher would indicate the treatment duration of 2 years was not feasible, and was evaluated under a binomial test using a one-sided α = 0.025.ResultsOverall, 162 patients initiated palbociclib; over half had stage III disease (52%) and most received prior chemotherapy (80%). A total of 102 patients (63%) completed 2 years of palbociclib; 50 patients discontinued early for protocol-related reasons (31%, 95% CI 24% to 39%, P = 0.001), and 10 discontinued due to protocol-unrelated reasons. The cumulative incidence of protocol-related discontinuation was 21% (95% CI 14% to 27%) at 12 months from start of treatment. Rates of palbociclib-related toxicity were congruent with the metastatic experience, and there were no cases of febrile neutropenia. Ninety-one patients (56%) required at least one dose reduction.ConclusionAdjuvant palbociclib is feasible in early breast cancer, with a high proportion of patients able to complete 2 years of therapy. The safety profile in the adjuvant setting mirrors that observed in metastatic disease, with approximately half of the patients requiring dose-modification. As extended duration adjuvant palbociclib appears feasible and tolerable for most patients, randomized phase III trials are evaluating clinical benefit in this population.Clinicaltrials.gov registrationNCT02040857. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
